Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM II
ISRCTN17633610Phase 3Completed
- Sponsor
- TEAM II Study Group
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane and ibandronate in breast cancer (4 arms), sponsored by TEAM II Study Group. Primary endpoints: Objective response rate of primary breast tumor by palpation and Three-year disease-free survival. Started Oct 2006; status: completed.
02
Drugs
exemestaneibandronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN17633610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17633610.